Skip to main content

Blogs

Understanding 503A and 503B in Telehealth

July 13, 2026

As cash-pay telehealth expands into weight management, peptides , and longevity, pharmacy and fulfillment models have become a bigger part of the infrastructure behind care.

That makes one distinction especially important: compounding under Section 503A and compounding by a Section 503B outsourcing facility operate under different federal frameworks.

The difference is more than pharmacy terminology. It can shape how a treatment program is structured, how prescriptions and pharmacy workflows interact, and how information moves through the patient journey. For organizations launching or expanding programs, the pharmacy pathway belongs in the operating model from day one.

503A and 503B Support Different Compounding Models

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act set up separate frameworks under which compounded drugs can qualify for exemptions from certain federal drug requirements. Here is how they compare:

Neither pathway makes a compounded drug FDA-approved.

For telehealth organizations, the key point is not the classification itself. It is that different compounding models bring different requirements and dependencies into the workflows around a treatment program.

503A compounding pharmacy
503B outsourcing facility

Who

State-licensed pharmacy or physician
Facility registered with FDA as an outsourcing facility

Prescriptions

Compounds based on a valid prescription for an identified individual patient; limited anticipatory compounding allowed based on prescription history
May compound with or without patient-specific prescriptions

Primary oversight

Mainly state boards of pharmacy
FDA, including current good manufacturing practice (CGMP) requirements, inspections, and product reporting

Bulk ingredients

Must have a USP/NF monograph, be a component of an FDA-approved drug, or appear on the 503A Bulks List
Must appear on the 503B bulks list or be used to make a drug on FDA's shortage list

FDA-approved?

Yes
No

Why This Matters Right Now

Both lists are in motion in 2026. In July, an FDA advisory committee recommended adding six peptides, including BPC-157, to the 503A Bulks List; the FDA has not yet acted. In April, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list , which would block outsourcing facilities from compounding them from bulk ingredients.

The same therapy can face very different rules depending on which pathway supplies it, and those rules can change mid-program.

The Pharmacy Pathway Shapes the Workflow

Telehealth brings several parts of care into one digital experience: intake , provider review , prescribing, commerce, pharmacy routing , and patient communication. How those steps connect matters.

When a program relies on patient-specific prescribing, the technology behind it has to track clinical review and prescription status as the patient moves toward fulfillment.

A 503B outsourcing facility may work differently, because qualifying drugs can be produced without patient-specific prescriptions. But that does not make every drug or bulk substance eligible under 503B. What applies still depends on the drug, its ingredients, and how it is compounded and distributed.

So the pharmacy relationship should not be treated as an isolated step at the end of the journey. The infrastructure behind a program needs to reflect the workflow it actually uses.

More Pharmacy Relationships Can Mean More Complexity

Organizations work with multiple pharmacy partners for many reasons. But adding a pharmacy does not automatically create a simple backup.

Switching pharmacies, or switching compounding models, can ripple across prescribing, routing, fulfillment, order status , and patient communication. Those dependencies get harder to manage when commerce, clinical workflows, pharmacy operations, and messaging live in separate systems.

Pharmacy flexibility belongs in the broader operating model, not just the vendor decision. The right infrastructure lets teams adapt when a pharmacy relationship or fulfillment workflow changes, without rebuilding the experience around it.

Clear Communication Matters

Regulatory accuracy is part of supporting compounded care. A compounded drug is not FDA-approved because it comes from a particular pathway; the FDA notes that compounded drugs do not go through the same premarket review for safety, effectiveness, and quality as approved drugs.

Keeping patient communication accurate gets harder as treatment categories, pharmacy partners, and rules change. One change behind the scenes can affect product pages, intake questions, and patient-facing claims all at once. When those systems are disconnected, keeping them aligned becomes another manual task.

Connected infrastructure makes it easier to keep every part of a program in sync as requirements and workflows evolve.

Compliant Care Starts With the Right Infrastructure

As cash-pay healthcare expands into new categories and pharmacy pathways, the infrastructure behind each program has to support the workflows and requirements that come with them.

Telegra connects healthcare commerce, provider workflows, pharmacy routing, patient experience, and operations in one platform, so organizations can build compliant care without relying on disconnected systems. Whether you are launching a new program or adapting an existing one, Telegra provides the connected foundation from intake through fulfillment.

Build compliant care with Telegra: Get Started.

Ready to own your stack?

See how Telegra's infrastructure keeps operations running when regulations shift.